Scott Isaacs

3 weeks ago | nature.com | Jeffrey V. Lazarus |Paul Brennan |Philippa Matthews |Juan Vaz |Scott Isaacs |Michael Roden | +6 more

Reducing the stigma and discrimination that people living with liver conditions experience requires rethinking how diagnoses, diseases, etiologies and circumstances are perceived — a shift that begins with the language used to name and describe them. You have full access to this article via your institution.

Mar 20, 2025 | healio.com | Michael Monostra |Richard Smith |Scott Isaacs

Key takeaways: Machine learning models identifying significant biomarkers were highly accurate at predicting MASLD and hepatic fibrosis. More research is needed assessing the models in a larger population. Machine learning may help identify biomarkers and develop predictive models that could assist in the diagnosis of metabolic dysfunction-associated steatotic liver disease and hepatic fibrosis, researchers reported.

Feb 25, 2025 | medscape.com | Carol H. Wysham |Scott Isaacs

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carol H. Wysham, MD: Hello. I'm Dr Carol Wysham. Welcome to season three of the Medscape InDiscussion: Type 2 Diabetes podcast series. Today, we'll discuss incorporating screening and management of metabolic dysfunction–associated fatty liver disease in endocrine practice. First, let me introduce my guest, Dr Isaacs.

Jul 15, 2024 | healio.com | Scott Isaacs |Heather Biele

You've successfully added Liver/Biliary Disorders to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Metabolic dysfunction-associated steatotic liver disease is a public health threat, affecting 30% to 38% of the adult population globally.

Aug 15, 2023 | healio.com | Michael Monostra |Richard Smith |Scott Isaacs |Laura Dichtel

Source/Disclosures Disclosures: Dichtel reports receiving donated identical growth hormone and placebo from Pfizer and donated LiverMultiScan analysis from Perspectum Ltd.; receiving research support from Lumos Pharma, Perspectum Ltd. and Recordati; owning equity in Marea Therapeutics; and being a Mass General Brigham Innovation Fellow hosted by venture capital firm Third Rock Ventures. Please see the study for all other authors’ relevant financial disclosures.